Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Company Overview

Monopar Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to developing novel targeted therapies for the treatment of cancer. The company’s research program focuses on exploiting unique vulnerabilities in tumor biology to enhance the efficacy and safety profile of its candidates. Monopar’s approach seeks to deliver precision medicines that address unmet needs in oncology by modulating the tumor microenvironment and leveraging insights into cancer stem cell biology.

Central to Monopar’s pipeline is MNPR-101, an orally administered small molecule designed to selectively bind and activate retinoic acid receptor pathways, aiming to induce differentiation of tumor cells while sparing healthy tissue. Additional assets in preclinical and early clinical stages include combination strategies that pair targeted inhibitors with immune modulators or standard chemotherapeutics. These programs reflect Monopar’s commitment to advancing therapies capable of improving long‐term outcomes for patients with solid tumors and hematologic malignancies.

Founded in 2014 and headquartered in San Francisco, Monopar maintains strategic collaborations with leading academic and research institutions across North America and Europe. These partnerships support the company’s translational efforts, enabling access to specialized clinical trials and biomarker platforms. Monopar’s multi‐site presence allows it to engage in diverse patient populations and accelerate enrollment in pivotal studies.

Under the leadership of Chief Executive Officer Domenico DiMarzo and Chief Scientific Officer Dr. Lee Rosen, Monopar has built a management team with extensive experience in oncology drug development, regulatory affairs, and commercialization. Guided by a board of directors and scientific advisory board comprised of industry veterans, the company continues to pursue its mission of delivering next‐generation cancer treatments to patients worldwide.

Key Stats

• Today's Range: $35.37 to $37.78
• 50-Day Range: $30.01 to $44.96
• 52-Week Range: $1.72 to $54.30
• Volume: 49,658 shs
• Average Volume: 359,486 shs
• Market Capitalization: $227.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Moderate Buy

Monopar Therapeutics Stock Analysis - MarketRank™

Monopar Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 381st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Monopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Monopar Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($1.65) to ($2.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monopar Therapeutics is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monopar Therapeutics is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monopar Therapeutics has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.63% of the float of Monopar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monopar Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monopar Therapeutics has recently decreased by 25.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monopar Therapeutics does not currently pay a dividend.

Dividend Growth

Monopar Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.63% of the float of Monopar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monopar Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monopar Therapeutics has recently decreased by 25.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

Monopar Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Monopar Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.50% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.83% of the stock of Monopar Therapeutics is held by institutions.

MNPR Stock Analysis - Frequently Asked Questions

How have MNPR shares performed this year?

Monopar Therapeutics' stock was trading at $22.00 at the start of the year. Since then, MNPR stock has increased by 69.1% and is now trading at $37.20.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced its earnings results on Tuesday, May, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.27.

When did Monopar Therapeutics' stock split?

Shares of Monopar Therapeutics reverse split on the morning of Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Does Monopar Therapeutics have any subsidiaries?

Monopar Therapeutics subsidiaries include Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.

When did Monopar Therapeutics IPO?

Monopar Therapeutics (MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNPR
• CIK: 1645469
• Web: www.monopartx.com
• Phone: 847-388-0349
• Fax: N/A
• Employees: 10
• Year Founded: 2014

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $76.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +61.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.39%
• Return on Assets: -51.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 36.91
• Quick Ratio: 36.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.02 per share
• Price / Book: 4.12

Miscellaneous

• Outstanding Shares: 6,120,000
• Free Float: 4,861,000
• Market Cap: $227.66 million
• Optionable: Not Optionable
• Beta: 1.01